Compare Amgen, Inc. (AMGN) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs HP Inc — how do they compare? Amgen, Inc. trades at $356.18 (market cap $196.12B), while HP Inc trades at $24.44 (market cap $22.15B). The key difference: Amgen, Inc. is far larger — about 8.9× HP Inc's market cap, and HP Inc pays the higher dividend (4.95%). Which is the better fit depends on your goals.
| AMGN | HPQ | |
|---|---|---|
Market Cap | $196.12B | $22.15B |
Sector | Health | Technology |
52-Week High | $388.16 | $29.35 |
52-Week Low | $271.18 | $18.20 |
Enterprise Value | $241.41B | $29.31B |
Dividend Yield | 2.77% | 4.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HPQ trades at $24.22, up 0.37% today, with a bullish technical outlook and strong recent earnings beats. The stock shows attractive valuation with a P/E of 8.97 and P/S of 0.4, supported by consistent operating cash flow of $3.7B in 2025. Recent news highlights HP's AI PC partnerships and dividend yield near 5%, though revenue growth remains modest amid industry headwinds.
Outlook is cautiously positive given low valuation and dividend appeal, but risks include PC market volatility and competitive pressures. Analyst consensus is mixed with a $22 price target below current levels, suggesting limited near-term upside despite fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
